Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.

Expert opinion on drug safety - 1 Sept 2014

Rutkowski Piotr, Blank Christian

Abstract excerpt

INTRODUCTION: V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors are emerging as the standard of care for treating advanced melanomas harboring the BRAF V600 oncogenic mutation. Dabrafenib is the second approved selective BRAF inhibitor (after vemurafenib) for the treatment of unresectable or metastatic BRAF V600-positive melanoma. AREAS COVERED: This review covers the current data on the efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Imidazoles
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Skin Neoplasms

Source

Identifiers

PMID: 25014231
DOI: 10.1517/14740338.2014.939954

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.PMID 25014231Read ↗

Dabrafenib for the treatment of melanoma.Semantic proximity Read ↗

Dabrafenib therapy for advanced melanoma.Semantic proximity Read ↗

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.Semantic proximity Read ↗

Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.Semantic proximity Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.Semantic proximity Read ↗

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.Semantic proximity Read ↗

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.Semantic proximity Read ↗

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.Semantic proximity Read ↗

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.Semantic proximity Read ↗

Vemurafenib/dabrafenib and trametinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.